We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
-13.67%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$237M
AUM Growth
-$42.4M
Cap. Flow
+$14.9M
Cap. Flow %
6.3%
Top 10 Hldgs %
74.51%
Holding
22
New
4
Increased
7
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
TIL icon
Instil Bio
TIL
+$14.1M
2
ZGNX
Zogenix, Inc.
ZGNX
+$8.71M
3
KROS icon
Keros Therapeutics
KROS
+$6.93M
4
AXSM icon
Axsome Therapeutics
AXSM
+$2.22M
5
MCRB icon
Seres Therapeutics
MCRB
+$2.21M

Top Sells

Rank Stock Value
1
KPTI icon
Karyopharm Therapeutics
KPTI
+$10.9M
2
FOLD
Amicus Therapeutics
FOLD
+$8.15M
3
TRIL
Trillium Therapeutics Inc.
TRIL
+$1.92M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$1.84M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$792K

Sector Composition

Rank Sector Weight
1 Healthcare 94.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$23.5B
$32.8M 13.81%
961,797
– –
ZGNX
2
DELISTED
Zogenix, Inc.
ZGNX
$27.4M 11.56%
1,405,259
+424,614
+43% +$8.71M
IOVA icon
3
Iovance Biotherapeutics
IOVA
$2.23B
$17.9M 7.55%
565,890
– –
ALLK
4
DELISTED
Allakos
ALLK
$16.9M 7.14%
147,662
– –
AXSM icon
5
Axsome Therapeutics
AXSM
$11.8B
$14.2M 6%
251,598
+31,500
+14% +$2.22M
TRIL
6
DELISTED
Trillium Therapeutics Inc.
TRIL
$14.2M 5.99%
1,323,181
-155,000
-10% -$1.92M
ARGX icon
7
argenx
ARGX
$53.8B
$14.2M 5.97%
51,450
+1,500
+3% +$474K
TIL icon
8
Instil Bio
TIL
$50.3M
$13.8M 5.81%
+27,500
New +$14.1M
COGT icon
9
Cogent Biosciences
COGT
$6.68B
$13.7M 5.77%
1,558,975
– –
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11.6M 4.9%
67,800
+7,300
+12% +$1.45M
ACAD icon
11
Acadia Pharmaceuticals
ACAD
$4.38B
$11.2M 4.7%
432,317
-18,000
-4% -$792K
AMRN
12
Amarin Corp
AMRN
$292M
$9.99M 4.21%
80,412
+5,000
+7% +$672K
ENTA icon
13
Enanta Pharmaceuticals
ENTA
$400M
$8.44M 3.56%
171,147
+20,714
+14% +$1.03M
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$7.79M 3.29%
788,980
-526,415
-40% -$8.15M
MCRB icon
15
Seres Therapeutics
MCRB
$51.6M
$7.27M 3.06%
17,651
+4,800
+37% +$2.21M
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.13M 3.01%
175,000
-40,000
-19% -$1.84M
KROS icon
17
Keros Therapeutics
KROS
$211M
$6.73M 2.84%
+109,333
New +$6.93M
VRNA
18
DELISTED
Verona Pharma
VRNA
$702K 0.3%
83,944
-16,056
-16% -$133K
VRDN icon
19
Viridian Therapeutics
VRDN
$1.99B
$581K 0.24%
35,092
– –
PNT
20
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$526K 0.22%
+50,000
New +$678K
ATXS
21
DELISTED
Astria Therapeutics
ATXS
$154K 0.06%
+8,861
New +$160K
KPTI icon
22
Karyopharm Therapeutics
KPTI
$216M
– –
-46,823
Closed -$10.9M

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q1 2021 Portfolio in Review

As of Q1 2021, Fairmount Funds Management held 22 positions worth $237M, down 15% from $280M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Fairmount Funds Management deployed $14.9M of net new capital in Q1 2021, opening 4 new positions and adding to 7 existing holdings. Its largest new stake was Instil Bio: 27,500 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $8.15M trimmed.

  • Fairmount Funds Management's largest Q1 2021 buy was Instil Bio: 27,500 shares worth $13.8M.
  • Fairmount Funds Management added most to Zogenix, Inc. in Q1 2021, an estimated $8.71M increase.
  • Fairmount Funds Management's biggest Q1 2021 reduction was Amicus Therapeutics, cutting an estimated $8.15M.
  • Fairmount Funds Management fully exited Karyopharm Therapeutics in Q1 2021, selling an estimated $10.9M.
  • Fairmount Funds Management's ten largest holdings make up 75% of its $237M portfolio in Q1 2021.
  • Fairmount Funds Management opened 4 new positions and closed 1 in Q1 2021.
  • Fairmount Funds Management's portfolio value fell 15% quarter-over-quarter to $237M.

Based on Fairmount Funds Management's 13F filing for Q1 2021, filed 14 May 2021.